SS-31 vs MOTS-c

Overview

SS-31 (elamipretide) is a synthetic mitochondria-targeted peptide in clinical development for mitochondrial diseases, while MOTS-c is an endogenous mitochondrial-derived peptide being studied for metabolic and longevity effects. Both target mitochondrial function through different mechanisms.

Important distinction: SS-31 is in active clinical development with Phase 2/3 data; MOTS-c research is earlier stage with primarily preclinical data.

Key Facts

Aspect	SS-31 (Elamipretide)	MOTS-c
Type	Synthetic peptide	Endogenous (encoded in mitochondrial DNA)
Structure	Tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2)	16 amino acids
Target	Inner mitochondrial membrane	Systemic metabolic effects
FDA Status	Investigational (Phase 2/3)	Not in clinical development
Developer	Stealth BioTherapeutics	Research compound

Mechanism Comparison

Aspect	SS-31	MOTS-c
Primary Target	Cardiolipin (inner mitochondrial membrane)	AMPK pathway, nuclear gene expression
Action Site	Mitochondria (direct)	Systemic (indirect mitochondrial benefit)
Mechanism	Stabilizes mitochondrial structure	Metabolic regulation, exercise mimetic
Effect on ROS	Reduces oxidative stress	Reduces oxidative stress
Endogenous	No (synthetic)	Yes (naturally produced)

How They Work

SS-31 (Elamipretide):

• Cell-penetrating peptide that concentrates in mitochondria
• Binds cardiolipin on inner mitochondrial membrane
• Stabilizes electron transport chain
• Reduces reactive oxygen species production
• Improves ATP synthesis efficiency
• Does not accumulate based on membrane potential (unique)

MOTS-c:

• Mitochondrial-derived peptide (MDP)
• Encoded in 12S rRNA gene of mitochondrial DNA
• Activates AMPK (metabolic master switch)
• Regulates nuclear gene expression (retrograde signaling)
• “Exercise mimetic” - mimics some metabolic effects of exercise
• Levels decline with age

Evidence Quality

SS-31 Research

Trial Type	Status	Key Findings
Phase 1	Completed	Safety and mitochondrial uptake
Phase 2 (Barth Syndrome)	Completed	Some functional improvements
Phase 2 (Heart Failure)	Completed	Mixed results
Phase 3 (Barth)	Ongoing	Primary endpoint data pending
Kidney disease trials	Ongoing	Investigating renal protection

Clinical evidence:

• Multiple Phase 2 trials completed
• Some positive signals in mitochondrial diseases
• Heart failure trials had mixed results
• Active clinical development continues
• Safety profile established in trials

MOTS-c Research

Study Type	Status	Key Findings
Discovery/characterization	Published	Identified 2015, mechanism described
Animal metabolic studies	Multiple	Improved insulin sensitivity, exercise effects
Aging studies (animal)	Some	Healthspan extension in mice
Human trials	Very limited	Small studies, early stage

Research summary:

• Discovered relatively recently (2015)
• Primarily preclinical data
• Strong mechanistic rationale
• Very limited human data
• No active clinical development programs

Evidence Strength Comparison

Factor	SS-31	MOTS-c
Clinical trial data	Moderate (Phase 2/3)	Very limited
Human safety data	Established	Very limited
Preclinical data	Extensive	Growing
Mechanism understanding	Well-characterized	Well-characterized
Overall quality	Moderate	Low

Indications Being Studied

SS-31 Clinical Targets

Indication	Status	Rationale
Barth Syndrome	Phase 3	Primary mitochondrial disease
Heart failure	Phase 2 (completed)	Mitochondrial dysfunction in HF
Dry AMD	Phase 2	Retinal mitochondrial health
Primary mitochondrial myopathy	Phase 2	Mitochondrial disease
Acute kidney injury	Phase 2	Renal mitochondrial protection

MOTS-c Research Focus

Area	Evidence Level	Rationale
Metabolic disease	Preclinical	AMPK activation, insulin sensitivity
Aging/longevity	Preclinical	Age-related decline, healthspan
Exercise performance	Preclinical	Exercise mimetic effects
Osteoporosis	Early research	Bone metabolism effects

Side Effects

SS-31 (From Clinical Trials)

Side Effect	Incidence	Notes
Injection site reactions	Common	Transient
Headache	Reported	Mild-moderate
Fatigue	Reported	—
Nausea	Reported	—

Safety profile: Generally well-tolerated in clinical trials with no major safety signals.

MOTS-c (Very Limited Data)

Aspect	Information
Human safety data	Minimal
Animal toxicity	No major concerns reported
Theoretical concerns	Unknown long-term effects
Endogenous nature	May suggest better tolerability

Longevity/Aging Context

SS-31 for Aging

Factor	Evidence
Healthspan studies (animal)	Some positive effects
Mitochondrial aging	Targets age-related dysfunction
Human aging trials	Not specifically conducted
Anti-aging application	Theoretical/off-label interest

MOTS-c for Aging

Factor	Evidence
Age-related decline	MOTS-c levels decrease with age
Healthspan (mice)	Extended in some studies
Replacement rationale	Restoring youthful levels
Human aging data	Very limited

Administration Comparison

Factor	SS-31	MOTS-c
Route	Subcutaneous, IV	Subcutaneous (research)
Half-life	Hours	Longer (peptide)
Stability	Stable	Requires proper storage

Availability Comparison

Factor	SS-31	MOTS-c
Legal status	Investigational drug	Research chemical
Clinical access	Via trials or named patient	Research only
Research chemical	Available	Available
Quality assurance	High (clinical-grade in trials)	Variable
Cost	High (if accessible)	Variable

Development Path

SS-31 Timeline

Milestone	Status
Discovery	Completed (2000s)
Phase 1	Completed
Phase 2	Multiple completed
Phase 3	Ongoing (Barth Syndrome)
Potential approval	Possible if trials succeed

MOTS-c Path

Status	Information
Discovery	2015
Preclinical	Active
Clinical development	Not formally initiated
Commercialization	None planned

Who Might Consider Each

SS-31 (Clinical Context):

• Patients with specific mitochondrial diseases
• Access through clinical trials
• Named patient/compassionate use (some jurisdictions)
• Requires physician involvement

MOTS-c (Research Context):

• Currently research/experimental only
• Longevity research community interest
• No established clinical protocols
• High uncertainty

Summary

Factor	SS-31 (Elamipretide)	MOTS-c
Evidence quality	Moderate (Phase 2/3)	Low (preclinical)
Mechanism	Direct mitochondrial targeting	Systemic metabolic effects
Origin	Synthetic	Endogenous (mitochondrial DNA)
Clinical development	Active	Not active
Human safety data	Established	Minimal
Approval status	Investigational	Research only
Accessibility	Clinical trials	Research chemical

Key takeaway: SS-31 is further along in clinical development with established safety data and potential for approval in mitochondrial diseases. MOTS-c has compelling preclinical data as an endogenous peptide but lacks clinical development. Both represent promising approaches to mitochondrial health and aging, but at very different stages of validation.

---

This comparison is for educational purposes only. SS-31 is an investigational drug. MOTS-c is a research compound. Neither is FDA-approved for any indication. Consult a healthcare provider for appropriate treatment.